Holen Sie sich die Stockscreener-App
5.91
3.75%
-0.23
Schlusskurs vom Vortag:
$6.14
Offen:
$6.18
24-Stunden-Volumen:
140.49K
Relative Volume:
0.04
Marktkapitalisierung:
$49.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.82M
KGV:
-5.1548
EPS:
-1.1465
Netto-Cashflow:
$-8.00M
1W Leistung:
+10.88%
1M Leistung:
-9.36%
6M Leistung:
+105.21%
1J Leistung:
+155.84%
1-Tages-Spanne:
$5.90
$6.35
1-Wochen-Bereich:
$5.0201
$6.35
52-Wochen-Spanne:
$0.72
$9.37
Edesa Biotech Inc Stock (EDSA) Company Profile
Firmenname
Edesa Biotech Inc
Sektor
Branche
Telefon
(905) 475-1234
Adresse
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
5.91 | 51.26M | 0 | -7.82M | -8.00M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
433.58 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.40 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.89 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.74 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Edesa Biotech Inc Aktie (EDSA) Neueste Nachrichten
Jobs Data: Is Edesa Biotech Inc still a buy after recent gains2026 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Edesa Biotech (NASDAQ:EDSA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Edesa Biotech (NASDAQ: EDSA) 2026 proxy seeks equity plan boost and director votes - Stock Titan
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Edesa Biotech to Showcase Positive ARDS Phase 3 Data at ATS 2026 Summit - TipRanks
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Upgraded to Sell at Wall Street Zen - Defense World
Edesa Biotech provides update on EB06 clinical study - TipRanks
Edesa Biotech Confirms Mid-2026 Start for Phase 2 Vitiligo Trial of EB06 - TipRanks
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment - ChartMill
Vitiligo drug study moves ahead as Edesa picks trial manager - Stock Titan
Gainers Report: Can Edesa Biotech Inc be the next market leader2026 Risk Factors & AI Powered Trade Plan Recommendations - baoquankhu1.vn
If You Invested $1,000 in Edesa Biotech Inc (EDSA) - Stock Titan
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Edesa Biotech Inc - GuruFocus
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Edesa Biot - GuruFocus
Volume Recap: Will Edesa Biotech Inc announce a stock split2026 Top Gainers & Weekly High Return Forecasts - baoquankhu1.vn
Bull Bear: Will Edesa Biotech Inc announce a stock splitPortfolio Gains Report & Daily Growth Stock Tips - baoquankhu1.vn
Perceptive Advisors stake: 563,239 shares in EDESA (NASDAQ: EDSA) - Stock Titan
EDSA SEC FilingsEdesa Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Edesa Biotech (EDSA) president buys 2,000 shares in open market - Stock Titan
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7% - MarketBeat
Edesa Biotech (EDSA) CEO adds 1,000 shares in open-market buy - Stock Titan
Best Biotech Stocks To Follow Today – March 7th - Defense World
Edesa Biotech’s Paridiprubart Trial Success Spurs Market Optimism - StocksToTrade
Edesa Biotech Gains Ground with Positive Clinical and Financial News - timothysykes.com
Will Edesa Biotech Inc. stock attract more institutional investorsPortfolio Performance Report & Weekly Return Optimization Plans - Naître et grandir
Best Biotech Stocks To Follow TodayMarch 7th - MarketBeat
Edesa Biotech Surges Following Promising Clinical Data in ARDS Treatment - StocksToTrade
Edesa Biotech Advances on Promising Drug Trial Results - timothysykes.com
Velan Capital Investment Management LP Increases Stake in Edesa Biotech Inc - GuruFocus
Edesa Biotech reports FQ1 net loss of $2.2 million - MSN
Price Action: Will Edesa Biotech Inc announce a stock splitJuly 2025 Earnings & High Yield Equity Trading Tips - baoquankhu1.vn
Edesa Biotech (NASDAQ:EDSA) CEO Pardeep Nijhawan Acquires 10,000 Shares - MarketBeat
Edesa Biotech (EDSA) CEO-linked entity adds 10,000 shares in open-market buy - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aug Mood: Can Edesa Biotech Inc be the next market leaderWatch List & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Intraday SessionFirefly Neuroscience (NASDAQ:AIFF), AN2 Thera - Benzinga
Edesa Biotech CEO Makes Bold Insider Move With Fresh Share Purchase - TipRanks
FY2026 EPS Forecast for Edesa Biotech Decreased by Analyst - Defense World
CEO-linked entity buys 10,000 Edesa Biotech (EDSA) shares - Stock Titan
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving PremarketArbutus Biopharma (NA - Benzinga
Edesa Biotech (NASDAQ: EDSA) CEO adds 3,000 shares in open-market purchases - Stock Titan
Point72 group (NASDAQ: EDSA) reports 600,000 shares, 7.2% stake - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Velan Capital details Edesa Biotech (NASDAQ: EDSA) 9.99% stake - Stock Titan
Nijhawan group boosts Edesa Biotech (EDSA) stake to 19.99% in 13D/A - Stock Titan
Edesa Biotech (NASDAQ: EDSA) CEO adds 50,571 shares in open-market buys - Stock Titan
[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan
EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality - Research Tree
Edesa Biotech Advances with Promising Phase 3 Outcomes - StocksToTrade
Edesa Biotech’s Paridiprubart Phase 3 Success Drives Optimism - timothysykes.com
Finanzdaten der Edesa Biotech Inc-Aktie (EDSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Edesa Biotech Inc-Aktie (EDSA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nijhawan Pardeep | Chief Executive Officer |
Mar 10 '26 |
Buy |
6.60 |
1,000 |
6,599 |
628,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 05 '26 |
Buy |
3.90 |
10,000 |
39,000 |
402,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 04 '26 |
Buy |
4.26 |
10,000 |
42,560 |
392,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 03 '26 |
Buy |
3.63 |
10,000 |
36,300 |
382,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.00 |
2,000 |
4,000 |
627,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.28 |
1,000 |
2,280 |
372,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 27 '26 |
Buy |
2.22 |
30,000 |
66,696 |
371,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 26 '26 |
Buy |
1.58 |
20,571 |
32,480 |
615,797 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):